Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells

Nature Medicine

Volumn 11, Issue 10, 2005, Pages 1073-1081

  Cole, Caroline ^a,b   Qiao, Jian ^a   Kottke, Timothy ^a   Diaz, Rosa Maria ^a   Ahmed, Atique ^a   Sanchez Perez, Luis ^a,b   Brunn, Gregory ^a   Thompson, Jill ^a   Chester, John ^c   Vile, Richard G ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARANASE; INTERLEUKIN 12; RETROVIRUS VECTOR; THYMIDINE KINASE; VIRUS VECTOR;

ADSORPTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER; CELL TRANSFER; CORRELATION ANALYSIS; DRUG TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; IMMUNOCOMPETENCE; IN VIVO STUDY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; NEOPLASMS; ORGAN SPECIFICITY; RETROVIRIDAE; SENSITIVITY AND SPECIFICITY;

SIMPLEXVIRUS;

EID: 27144483926     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1297     Document Type: Article

References (50)

1. Vile, R.G., Russell, S.J. & Lemoine, N.R. Cancer gene therapy: hard lessons and new courses. Gene Ther. 7, 2-8 (2000).
2. Harrington, K. et al. Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery. Hum. Gene Ther. 13, 1263-1280 (2002).
3. Pizzato, M., Marlow, S.A., Blair, E.D. & Takeuchi, Y. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J. Virol. 73, 8599-8611 (1999).
4. Chester, J. et al. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat. Biotechnol. 20, 256-263 (2002).
5. Crittenden, M. et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic anti-tumor gene therapy. Cancer Res. 63, 3173-3180 (2003).
6. Harrington, K.J., Linardakis, E. & Vile, R.G. Transcriptional control: an essential component of cancer gene therapy strategies? Adv. Drug Deliv. Rev. 44, 167-184 (2000).
7. Rosenberg, S.A. & Dudley, M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101, Suppl. 2, 14639-14645 (2004).
8. Dudley, M.E. & Rosenberg, S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3, 666-676 (2003).
9. Yee, C., Riddell, S.R. & Greenberg, P.D. In vivo tracking of tumor-specific T cells. Curr. Opin. Immunol. 13, 141-146 (2001).
10. Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637-1644 (2000).
11. Dudley, M.E. et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24, 363-373 (2001).
12. Dudley, M.E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
13. + T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 173, 7209-7216 (2004).
14. Pizzato, M. et al. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Ther. 8, 1088-1096 (2001).
15. Weiss, R.A. & Chetankuma, S.T. Retrovirus receptors. Cell 82, 531-533 (1995).
16. Sasisekharan, R., Shriver, Z., Venkataraman, G. & Narayanasami, U. Roles of heparansulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2, 521-528 (2002).
17. Linardakis, E. et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res. 62, 5495-5504 (2002).
18. de Mestre, A.M., Khachigian, L.M., Santiago, F.S., Staykova, M.A. & Hulett, M.D. Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J. Biol. Chem. 278, 50377-50385 (2003).
19. Takeuchi, Y., Cosset, F.L., Lachmann, P.J., Okada, H., Weiss, R.A. & Collins, M.K.L. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68, 8001-8007 (1994).
20. Chong, H., Todryk, S., Hutchinson, G., Hart, I.R. & Vile, R.G. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther. 5, 223-232 (1998).
21. Vile, R.G. & Hart, I.R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53, 3860-3864 (1993).
22. Vile, R., Miller, N., Chernajovsky, Y. & Hart, I.R. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1, 307-316 (1994).
23. Diaz, R.M., Eisen, T., Hart, I.R. & Vile, R.G. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J. Virol. 72, 789-795 (1998).
24. Geijtenbeek, T.B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597 (2000).
25. Bobardt, M.D. et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18, 27-39 (2003).
26. Yotnda, P., Savoldo, B., Charlet-Berguerand, N., Rooney, C. & Brenner, M. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood 104, 2272-2280 (2004).
27. Walker, S.J., Pizzato, M., Takeuchi, Y. & Devereux, S. Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. J. Virol. 76, 6909-6918 (2002).
28. Saksela, O., Moscatelli, D., Sommer, A. & Rifkin, D.B. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J. Cell Biol. 107, 743-751 (1988).
29. Reiland, J. et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J. Biol. Chem. 279, 8047-8055 (2004).
30. Hulett, M.D. et al. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5, 803-809 (1999).
31. Miao, H.Q. et al. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int. J. Cancer 83, 424-431 (1999).
32. Vlodavsky, I. et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5, 793-802 (1999).
33. Tatsumi, T., Gambotto, A., Robbins, P.D. & Storkus, W.J. Interleukin 18 gene transfer expands the repertoire of anti tumor Th-1 type immunity elicited by dendritic cell based vaccines in association with enhanced therapeutic efficacy. Cancer Res. 62, 5853-5858 (2002).
34. Vile, R.G. et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71, 267-274 (1997).
35. Melcher, A. et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4, 581-587 (1998).
36. Todryk, S. et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol. 163, 1398-1408 (1999).
37. Robbins, P.F. et al. Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125-7130 (2004).
38. Daniels, G. et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol. 22, 1125-1132 (2004).
39. Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferations in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
40. Qiao, J., Diaz, R.M. & Vile, R. Success for gene therapy: render unto Caesar that which is Caesar's. Genome Biol. 5, 237-240 (2004).
41. Miller, D.G., Adam, M.A. & Miller, A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. 10, 4239-4242 (1990).
42. Blomer, U., Gruh, I., Witschel, H., Haverich, A. & Martin, U. Shuttle of lentiviral vectors via transplanted cells in vivo. Gene Ther. 12, 67-74 (2005).
43. Chernajovsky, Y., Gould, D.J. & Podhajcer, O.L. Gene therapy for autoimmune diseases: quo vadis? Nat. Rev. Immunol. 4, 800-811 (2004).
44. Morgenstern, J.P. & Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596 (1990).
45. Wagner, M.J., Sharp, J.A. & Summers, W.C. Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA 78, 1441-1445 (1981).
46. Markowitz, D., Goff, S. & Bank, A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400-406 (1988).
47. Miller, A.D. et al. Construction and properties of retroviral packaging cells based on gibbon ape leukemia virus. J. Virol. 65, 2220-2224 (1991).
48. Burns, J.C., Friedmann, T., Driever, W., Burrascano, M. & Yee, J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033-8037 (1993).
49. Hogquist, K.A. et al. T cell receptor antagonistic peptides induce positive selection. Cell 76, 17-27 (1994).
50. Altman, D.G. Analysis of survival times. in Practical Statistics for Medical Research. 365-395 (Chapman and Hall, London, 1991).